Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer

Abstract Hypopharyngeal squamous cell carcinoma (HPSCC) has a very poor prognosis. Local surgery may increase survival, but is often avoided due to significant post-op co-morbidities. Since prognostic markers are lacking, the aim was to find predictive biomarkers that identify patients whose respons...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael Mints, David Landin, Anders Näsman, Leila Mirzaie, Ramona Gabriela Ursu, Mark Zupancic, Linda Marklund, Tina Dalianis, Eva Munck-Wikland, Torbjörn Ramqvist
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7b38a5f9949a4258a73607c31b9902d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b38a5f9949a4258a73607c31b9902d9
record_format	dspace
spelling	oai:doaj.org-article:7b38a5f9949a4258a73607c31b9902d92021-12-02T10:49:22ZTumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer10.1038/s41598-020-80226-z2045-2322https://doaj.org/article/7b38a5f9949a4258a73607c31b9902d92021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80226-zhttps://doaj.org/toc/2045-2322Abstract Hypopharyngeal squamous cell carcinoma (HPSCC) has a very poor prognosis. Local surgery may increase survival, but is often avoided due to significant post-op co-morbidities. Since prognostic markers are lacking, the aim was to find predictive biomarkers that identify patients whose response to oncological treatment is poor and who may benefit from primary surgery to increase survival. Pretreatment biopsies from 23 HPSCC patients, 3 human papillomavirus (HPV) positive and 20 HPV-negative, were analyzed for expression of 750 mRNAs using the Nanostring nCounter IO360 panel in relation to 3-year survival. Validation was performed through immunohistochemistry (IHC) for HLA class I and S100A12 in 74 HPV-negative HPSCC samples. Clustering identified a subset of HPV-negative HPSCC with favorable prognosis and a gene expression signature overexpressing calgranulins and immune genes, distinct from that of HPV-positive HPSCC. Enrichment analysis showed immune signaling, including the tumor inflammation signature, to be enriched in surviving patients. IHC validation confirmed high S100A12 and HLA class I expression to correlate with survival in HPV-negative HPSCC. This shows that immune activity is strongly related to survival in HPV-negative HPSCC. Enrichment of the tumor inflammation signature indicates a potential benefit of immunotherapy. Low expression of both HLA class I and S100A12 could be used to select patients for local surgery.Michael MintsDavid LandinAnders NäsmanLeila MirzaieRamona Gabriela UrsuMark ZupancicLinda MarklundTina DalianisEva Munck-WiklandTorbjörn RamqvistNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Michael Mints David Landin Anders Näsman Leila Mirzaie Ramona Gabriela Ursu Mark Zupancic Linda Marklund Tina Dalianis Eva Munck-Wikland Torbjörn Ramqvist Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
description	Abstract Hypopharyngeal squamous cell carcinoma (HPSCC) has a very poor prognosis. Local surgery may increase survival, but is often avoided due to significant post-op co-morbidities. Since prognostic markers are lacking, the aim was to find predictive biomarkers that identify patients whose response to oncological treatment is poor and who may benefit from primary surgery to increase survival. Pretreatment biopsies from 23 HPSCC patients, 3 human papillomavirus (HPV) positive and 20 HPV-negative, were analyzed for expression of 750 mRNAs using the Nanostring nCounter IO360 panel in relation to 3-year survival. Validation was performed through immunohistochemistry (IHC) for HLA class I and S100A12 in 74 HPV-negative HPSCC samples. Clustering identified a subset of HPV-negative HPSCC with favorable prognosis and a gene expression signature overexpressing calgranulins and immune genes, distinct from that of HPV-positive HPSCC. Enrichment analysis showed immune signaling, including the tumor inflammation signature, to be enriched in surviving patients. IHC validation confirmed high S100A12 and HLA class I expression to correlate with survival in HPV-negative HPSCC. This shows that immune activity is strongly related to survival in HPV-negative HPSCC. Enrichment of the tumor inflammation signature indicates a potential benefit of immunotherapy. Low expression of both HLA class I and S100A12 could be used to select patients for local surgery.
format	article
author	Michael Mints David Landin Anders Näsman Leila Mirzaie Ramona Gabriela Ursu Mark Zupancic Linda Marklund Tina Dalianis Eva Munck-Wikland Torbjörn Ramqvist
author_facet	Michael Mints David Landin Anders Näsman Leila Mirzaie Ramona Gabriela Ursu Mark Zupancic Linda Marklund Tina Dalianis Eva Munck-Wikland Torbjörn Ramqvist
author_sort	Michael Mints
title	Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
title_short	Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
title_full	Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
title_fullStr	Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
title_full_unstemmed	Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
title_sort	tumour inflammation signature and expression of s100a12 and hla class i improve survival in hpv-negative hypopharyngeal cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7b38a5f9949a4258a73607c31b9902d9
work_keys_str_mv	AT michaelmints tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT davidlandin tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT andersnasman tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT leilamirzaie tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT ramonagabrielaursu tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT markzupancic tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT lindamarklund tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT tinadalianis tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT evamunckwikland tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer AT torbjornramqvist tumourinflammationsignatureandexpressionofs100a12andhlaclassiimprovesurvivalinhpvnegativehypopharyngealcancer
_version_	1718396599826120704

Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer

Ejemplares similares